Molecular epidemiology of VIM-1 producing Escherichia coli from Germany referred to the National Reference Laboratory

International Journal of Medical Microbiology : IJMM
M KaaseSören G Gatermann

Abstract

The distribution of carbapenemase genes in Escherichia coli strains isolated between September 2009 and May 2013 in Germany was investigated. Out of 192 isolates with carbapenemase production OXA-48 was found in 44.8%, VIM-1 in 18.8%, NDM-1 in 11.5% and KPC-2 in 6.8%. Patients with VIM-1 producing E. coli (n=36) differed from patients with OXA-48 by an older age, less frequent mention of travel history and an increased proportion of clinical over screening specimens. These data might indicate that introduction from abroad is of minor importance for VIM-1 producing E. coli compared to other carbapenemases. Multilocus sequence typing revealed that E. coli with VIM-1 were mostly multiclonal, emphasizing the role of horizontal gene transfer in its spread. Susceptibility testing of VIM-1 producing E. coli demonstrated aztreonam susceptibility in 55.6%. Among non-β-lactams susceptibility rates of >90% were observed for amikacin, tigecycline, colistin, fosfomycin and nitrofurantoin.

References

May 13, 2006·Molecular Microbiology·Thierry WirthMark Achtman
Dec 30, 2010·Antimicrobial Agents and Chemotherapy·Yvonne PfeiferLaurent Poirel
Mar 29, 2012·The Journal of Antimicrobial Chemotherapy·Jennie FischerBeatriz Guerra
Mar 19, 2013·Frontiers in Microbiology·Gopi Patel, Robert A Bonomo
Jun 15, 2013·Emerging Infectious Diseases·Nathalie TijetRoberto G Melano
Sep 18, 2013·Antimicrobial Agents and Chemotherapy·Jesús OteoUNKNOWN Spanish Collaborating Group for the Antibiotic Resistance Surveillance Program
Oct 16, 2013·Diagnostic Microbiology and Infectious Disease·Richard AschbacherElisabetta Pagani
Dec 4, 2013·Antimicrobial Agents and Chemotherapy·Giuseppe ValenzaChristiane Höller
Mar 25, 2014·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·I EhrhardW Sydow
May 29, 2014·Antimicrobial Agents and Chemotherapy·Ritu Banerjee, James R Johnson

❮ Previous
Next ❯

Citations

Sep 14, 2015·International Journal of Medical Microbiology : IJMM·Ulrich VogelMary Slack
Jul 2, 2016·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Dorina TimofteFelicia Toma
Nov 30, 2018·The Journal of Antimicrobial Chemotherapy·Felix LangeMartin Kaase
Jun 14, 2019·Clinical Microbiology Reviews·Amee R MangesJohann D D Pitout
Jan 18, 2017·The Journal of Antimicrobial Chemotherapy·Felix LangeMartin Kaase
Aug 21, 2018·Emerging Infectious Diseases·Philipp P KohlerUNKNOWN Toronto Invasive Bacterial Diseases Network (TIBDN)
Oct 3, 2018·Medizinische Klinik, Intensivmedizin und Notfallmedizin·R Köck, C Cuny
Jun 14, 2018·The Journal of Antimicrobial Chemotherapy·Felix LangeMartin Kaase

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

The Journal of Antimicrobial Chemotherapy
Jennie FischerBeatriz Guerra
Diagnostic Microbiology and Infectious Disease
Ana Paula D'Alincourt Carvalho-AssefElizabeth Andrade Marques
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
S ChoudhuryP U Krishnan
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
Abouddihaj BarguiguaMohammed Timinouni
© 2021 Meta ULC. All rights reserved